REG - Creo Medical Group - Exercise of Options

Creo MedicalAnnouncement

24/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211124:nRSX3350Ta&default-theme=true

RNS Number : 3350T  Creo Medical Group PLC  24 November 2021

 Creo Medical Group plc

("Creo" or the "Company")

 

Exercise of Options

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, confirms that it has issued, conditional
on admission, 108,000 new ordinary shares of 0.1 pence each in the capital of
the Company ("Ordinary Shares"), pursuant to the exercise of share options. It
is expected that admission of the Ordinary Shares will occur at 8:00 a.m. on
29 November 2021.

 

Following admission, the Company will have 181,009,186 Ordinary Shares in
issue. This figure of 181,009,186 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cenkos Securities plc                              +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Joint Broker)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000
 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. CROMA currently delivers bipolar radiofrequency ("RF")
energy for precise localised cutting and focused high frequency microwave
("MW") energy for controlled coagulation and ablation via a single accessory
port. This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with flexible,
accurate and controlled clinical solutions. The Group's three initial areas of
focus are (1) in the GI, (2) soft tissue ablation (including but not limited
to, the liver, pancreas, kidney) and (3) lung interventions for the resection
and/or ablation of pre-cancerous and cancerous lesions. The Directors believe
the Company's technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.

 

For more information about Creo Medical please see our website,
www.creomedical.com (http://www.creomedical.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZMZMRFKGMZM